Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
Clinical trial NCT07339839 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07339839
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-01
- Primary completion
- 2027-09-30
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.